首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1695957

全球 LAG-3 标靶治疗市场：剂量、专利、销售和临床试验洞察（2030 年）

Global LAG-3 Targeting Therapy Market, Drug Dosage, Patent, Sales & Clinical Trials Insight 2030

出版日期: 2025年04月01日 | 出版商:

KuicK Research | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

预计到 2030 年，LAG-3 标靶治疗的全球市场价值将超过 40 亿美元。

LAG-3标靶治疗在全球市场受到关注，因为它在治疗癌症、自体免疫疾病和发炎性疾病等多种疾病方面具有潜在的应用。一种称为淋巴细胞活化基因 3 (LAG-3) 的免疫检查点受体对于控制免疫反应至关重要。因此，已经开发出多种治疗方法来改变 LAG-3 活性，透过活化、消耗或抑制它，每种方法都有独特的治疗应用。其中最受欢迎的策略是 LAG-3 抑制，但 Immutep 开发的 LAG-3 活化和消耗也越来越流行。

在这个市场中，LAG-3 抑制仍然是最受欢迎的治疗策略，因为它旨在提高免疫系统识别和消除癌细胞的能力。这种方法主要使用单株抗体。此单株抗体旨在阻断 LAG-3 受体，有效地最大限度地发挥 T 细胞对肿瘤细胞的攻击作用。 ZGGS-15 等同时针对 TIGIT 和 LAG-3 的双特异性抗体是未来的创新疗法。苏州泽璟生物製药的ZGGS-15专门用于治疗实体肿瘤。双特异性抗体有可能透过同时针对两个免疫检查点路径来增强免疫疗法的疗效。

除了癌症之外，研究人员还在研究如何利用 LAG-3 来治疗自体免疫疾病和发炎疾病。儘管该研究领域仍处于早期阶段，但越来越多的证据表明，调节 LAG-3 可能对微生物疾病具有治疗价值。 LAG-3抑制被认为是克服肿瘤引起的免疫抑制的一种手段。

Opdualag 是抗 PD-1 单株抗体 nivolumab 与抗 LAG-3 单株抗体 leratolimab 的组合，是该领域的重要成功案例。 Opduralag 于 2022 年获批，预计当年销售额将超过 2.5 亿美元，2024 年将达到 9 亿美元。这一令人印象深刻的扩张预示着类似疗法的光明前景，也反映出 LAG-3 标靶疗法在肿瘤市场越来越受到认可。

目前，超过 35 个 LAG-3 标靶候选药物正在临床开发中，这表明人们对该领域的广泛兴趣和持续创新。再生元製药凭藉其主要候选药物之一 fianlimab 已成为该市场的主要参与者。目前，fianlimab 正处于 3 期试验阶段，正在针对多种癌症适应症进行评估，并有可能对治疗前景产生重大影响。 Immutep 的 IMP-761 是一流的 LAG-3 激动剂，也是一个令人兴奋的候选药物。 IMP-761 目前正在早期人体临床试验中进行安全性和有效性测试，随后将扩大用于治疗自体免疫疾病。

因此，LAG-3 标靶治疗的临床试验数量的增加和适应症的扩大表明该市场在未来几年将实现显着增长。单株抗体和双特异性抗体的融合，加上对 LAG-3 激动和消耗的持续追求，提供了广泛的治疗方法，可能会彻底改变癌症、自体免疫疾病等的治疗。随着研究的进展，LAG-3标靶治疗预计将在免疫肿瘤学和其他免疫相关疾病中变得越来越不可或缺，从而推动市场的进一步成长。

本报告研究了全球 LAG-3 标靶治疗市场，并概述了市场以及药物趋势、临床试验趋势、区域趋势以及参与市场的公司的竞争格局。

Global LAG-3 Targeting Therapies Market Opportunity By 2030: > USD 4 Billion
Global & Regional Market Insight
Approved Drug Global & Regional Sales Analysis
Approved LAG-3 Drug Dosing, Pricing & Sales Insight
Global LAG3 Inhibitors clinical Trials Insight By Company, Country, Indication and Phase
Insight On More Than 35 LAG-3 Targeted Therapies In Clinical Trials
Expected Completion Time For Key Drugs In Clinical Trials

The potential of LAG-3 targeting therapy to treat a number of ailments, particularly cancer, autoimmune diseases, and inflammatory diseases, has attracted a lot of attention to the global market. An immune checkpoint receptor called lymphocyte-activation gene 3 (LAG-3) is essential for controlling immune responses. As a result, a number of treatments have been developed to modify LAG-3 activity, either by activation, depletion, or inhibition, each with unique therapeutic uses. The most popular strategy among them is LAG-3 inhibition, but LAG-3 activation and depletion, both of which were developed by Immutep, are also becoming more popular.

In this market, LAG-3 inhibition is still the most popular therapeutic strategy because it aims to improve the immune system's capacity to recognize and eliminate cancer cells. The approach primarily involves the use of monoclonal antibodies, which are intended to inhibit the LAG-3 receptor, effectively maximizing T-cells to attack tumor cells. Bispecific antibodies, such as ZGGS-15, which targets both TIGIT and LAG-3, represent an upcoming and innovative class of therapies. Suzhou Zelgen Biopharmaceuticals' ZGGS-15 is specifically designed to treat solid tumors. Bispecific antibodies have the potential to increase the effectiveness of immune therapies by simultaneously targeting two immune checkpoint pathways, particularly for complex conditions like solid tumors that are typically more difficult to treat.

In addition to cancer, researchers are also looking into how LAG-3 targeting might be used to treat autoimmune and inflammatory disorders. Although research in this area is still in its early stages, there is also mounting evidence that suggests LAG-3 modulation may have therapeutic benefits in microbial diseases. The main focus, however, is still on cancer treatment, especially in the context of immunotherapy, where LAG-3 inhibition is thought to be a means of overcoming immune suppression brought on by tumors.

The drug Opdualag, which combines the anti-PD-1 monoclonal antibody nivolumab with the anti-LAG-3 monoclonal antibody relatlimab, is a significant success story in this field. Approved in 2022, Opdualag's revenue surpassed US$ 250 million that year, and in 2024, it exceeded US$ 900 million. This remarkable expansion indicates a promising future for similar treatments and reflects the growing acceptance of LAG-3 targeting therapies in the oncology market.

More than 35 LAG-3 targeting candidates are presently undergoing clinical development, demonstrating the expansive interest and continuous innovation in this area. Regeneron Pharmaceuticals is a major player in this market thanks to Fianlimab, one of its lead candidates. Fianlimab, which is presently undergoing Phase 3 trials, is being evaluated for a number of cancer indications and could have considerable effects on the treatment environment. Immutep's IMP-761, a first-in-class LAG-3 agonist, is another exciting candidate. IMP-761 is being tested for safety and effectiveness in humans in early phase trials, after which, the treatment will be expanded to autoimmune disorders.

Thus, the increasing number of clinical trials and the expanding therapeutic indications for LAG-3 targeting therapies indicate this market is positioned for substantial growth in the coming years. The amalgamation of monoclonal and bispecific antibodies, along with the ongoing pursuit of LAG-3 agonism and depletion, presents a wide array of potential treatments that could revolutionize the management of cancer, autoimmune diseases, and beyond. LAG-3 targeted therapies are anticipated to become increasingly essential in immuno-oncology and other immune-related disorders as research advances, propelling additional market growth.

1. Introduction to LAG-3 Targeting Therapies

1.1 LAG-3 As Therapeutic Target
1.2 LAG-3 Targeting Therapies - Mechanism Of Action
1.3 LAG-3 Targeting Approaches

2. Combination Strategies For LAG-3 Targeting Therapies

3. Global LAG-3 Targeting Therapy Market Scenario

3.1 Current Market Outlook
3.2 Future Market Outlook

4. LAG-3 Targeting Therapy Market Regional Analysis

4.1 US
4.2 EU
4.3 China
4.4 Australia
4.5 UK
4.6 Japan
4.7 Canada
4.8 South Korea

5. LAG-3 Targeting Therapy - Development Trends By Indication

5.1 Cancer
- 5.1.1 Lymphoma
- 5.1.2 Melanoma
- 5.1.3 Lung Cancer
- 5.1.4 Gastrointestinal Cancers
- 5.1.5 Head & Neck Cancer
5.2 Autoimmune & Inflammatory Diseases
5.3 Microbial Infections

6. Opdualag (Nivolumab & Relatlimab) - Overview, Pricing, Dosing & Sales Analysis

6.1 Overview & Patent Insight
6.2 Pricing & Dosing
6.3 Sales Insight

7. Global LAG-3 Targeting Therapies Clinical Trials Overview

7.1 By Phase
7.2 By Country
7.3 By Company
7.4 By Indication
7.5 By Priority Status
7.6 Patient Segment

8. Global LAG3 Targeting Therapies clinical Trials Insight By Company, Country, Indication & Phase

8.1 Research
8.2 Preclinical
8.3 Phase I
8.4 Phase I/II
8.5 Phase II
8.6 Phase II/III
8.7 Phase III

9. Marketed LAG-3 Inhibitor Clinical Insight

10. Global LAG-3 Targeting Therapy Market Dynamics

10.1 Market Drivers
10.2 Market Challenges

11. Competitive Landscape

11.1 ABL Bio
11.2 Agenus
11.3 Akeso Biopharma
11.4 Bristol-Myers Squibb
11.5 EpimAb Biotherapeutics
11.6 F-star Therapeutics
11.7 Immutep
11.8 Innovent Biologics
11.9 Shanghai Henlius Biotech
11.10 Y-Biologics

简介目录图表

List of Figures

Figure 1-1: LAG-3/MHC Class II Signaling Pathway
Figure 1-2: LAG-3 Targeted Therapy Landscape - Milestones
Figure 1-3: LAG-3 Inhibitor - Mechanism Of Action
Figure 1-4: LAG-3 Agonist - Mechanism Of Action
Figure 1-5: LAG-3 Depletion - Mechanism Of Action
Figure 1-6: Bispecific Antibodies - Binding Efficacy
Figure 2-1: Overview to LAG-3 Combinations
Figure 3-1: Global - LAG 3 Targeting Therapy Market Value (US$ Million), 2022-2024
Figure 3-2: Global - LAG 3 Targeting Therapy Market Value By Region (US$ Million), 2024
Figure 3-3: Global - LAG 3 Targeting Therapy Market Value By Region (%), 2024
Figure 3-4: Global - Quarterly LAG 3 Targeting Therapy Market Value (US$ Million), 2024
Figure 3-5: Global - LAG 3 Targeting Therapy Market Forecast (US$ Million), 2025 - 2030
Figure 3-6: Global LAG-3 Targeting Therapy Market - Future Outlook
Figure 4-1: EU - Research Institutes & Hospitals Conducting LAG-3 Therapy Clinical Trials
Figure 5-1: RELATIVITY-069 Phase 1/2 (NCT05255601) Study - Initiation & Completion Year
Figure 5-2: AK129-102 Phase 1/2 (NCT06642792) Study - Initiation & Completion Year
Figure 5-3: R3767-ONC-2011 Phase 3 (NCT05352672) Study - Initiation & Completion Year
Figure 5-4: R3767-ONC-2055 Phase 3 (NCT05352672) Study - Initiation & Completion Year
Figure 5-5: INCAGN 2385-201 Phase 1/2 (NCT04370704) Study - Initiation & Completion Year
Figure 5-6: R3767-ONC-2235 Phase 2/3 (NCT05785767) Study - Initiation & Completion Year
Figure 5-7: R3767-ONC-2236 Phase 2/3 (NCT05800015) Study - Initiation & Completion Year
Figure 5-8: R2810-ONC-1866 Phase 2 (NCT03916627) Study - Initiation & Completion Year
Figure 5-9: R2810-ONC-2266 Phase 2 (NCT06161441) Study - Initiation & Completion Year
Figure 5-10: RELATIVITY-104 Phase 2 (NCT04623775) Study - Initiation & Completion Year
Figure 5-11: RELATIVITY-1093 Phase 3 (NCT06561386) Study - Initiation & Completion Year
Figure 5-12: J23155 Phase 2 (NCT06205836) Study - Initiation & Completion Year
Figure 5-13: J1714 Phase 1b (NCT03044613) Study - Initiation & Completion Year
Figure 5-14: RELATIVITY-123 Phase 3 (NCT05328908) Study - Initiation & Completion Year
Figure 5-15: NP41300 Phase 1/2 (NCT04140500) Study - Initiation & Completion Year
Figure 5-16: LBL-007-CN-003 Phase 1b/2 (NCT05102006) Study - Initiation & Completion Year
Figure 5-17: HCC 18-139 Phase 2 (NCT04080804) Study - Initiation & Completion Year
Figure 5-18: IMP761-P001 Phase 1 (NCT06637865) Study - Initiation & Completion Year
Figure 6-1: Opdualag - Approval Year by Region
Figure 6-2: Opdualag - Estimated Minimum Market Exclusivity Year By Region
Figure 6-3: US - Cost Per Unit & Supply Of Opdualag (US$), April'2025
Figure 6-4: Cost Per Unit & Supply Of Opdualag (US$), April'2025
Figure 6-5: Global - Opdualag Annual Sales (US$ Million), 2022-2024
Figure 6-6: Global - Opdualag Sales (US$ Million), Q1-Q4'2024
Figure 6-7: Opdualag - US v/s ROW Sales (US$ Million), 2024
Figure 6-8: Global - Opdualag Sales (US$ Million), 2024
Figure 6-9: US - Opdualag Sales (US$ Million), 2022-2024
Figure 6-10: US - Opdualag Sales (US$ Million), Q1-Q4'2024
Figure 6-11: ROW - Opdualag Sales (US$ Million), 2022-2024
Figure 6-12: ROW - Opdualag Sales (US$ Million), Q1-Q4'2024
Figure 7-1: Global - LAG-3 Inhibitor Clinical Trials By Phase (Numbers), 2025 - 2030
Figure 7-2: Global - LAG-3 Inhibitor Clinical Trials By Country (Numbers), 2025 - 2030
Figure 7-3: Global - LAG-3 Inhibitor Clinical Trials By Company (Numbers), 2025 - 2030
Figure 7-4: Global - LAG-3 Inhibitor Clinical Trials By Indication (Numbers), 2025 - 2030
Figure 7-5: Global - LAG-3 Inhibitor Clinical Trials By Priority Status (Numbers), 2025 - 2030
Figure 7-6: Global - LAG-3 Inhibitor Clinical Trials By Patient Segment (Numbers), 2025 - 2030
Figure 10-1: Global LAG-3 Targeting Therapy Market - Drivers & Opportunities
Figure 10-2: Global LAG-3 Targeting Therapy Market - Challenges & Restraints

List of Tables

Table 2-1: Ongoing Preclinical & Clinical Trials For Combination of LAG-3 inhibitors, April'2025
Table 4-1: US - Ongoing Clinical Trials For LAG-3 Targeting Therapies, April'2025
Table 4-2: China - Ongoing Clinical Trials For LAG-3 Targeting Therapies, April'2025
Table 4-3: Immutep - Active Patents By Region
Table 5-1: Melanoma - Some Ongoing Clinical Trials For LAG-3 Inhibitors, April'2025
Table 6-1: Opdualag - Maximum Infusion Volumes & Concentration Ranges By Patient Group 1
Table 6-2: Opdualag - Recommended Dosage Modifications For Adverse Reactions

02-2729-4219

+886-2-2729-4219

License/价格

全球 LAG-3 标靶治疗市场：剂量、专利、销售和临床试验洞察（2030 年）

Global LAG-3 Targeting Therapy Market, Drug Dosage, Patent, Sales & Clinical Trials Insight 2030

目录

第1章 LAG-3标靶治疗的简介

第2章 LAG-3标靶治疗的组合策略

第3章 LAG-3标靶治疗的全球市场Scenario

第4章 LAG-3标靶治疗市场地区分析

第5章 LAG-3标靶治疗- 各适应症的开发趋势

第6章 Opdualag（Nivolumab 和 Lelatolimab）- 概述、价格、剂量、销售分析

第7章标靶治疗的临床试验概要全球LAG-3

第8章全球LAG-3标靶治疗的临床试验相关考察:企业，国家，适应症，各相

第9章已上市LAG-3抑制剂的临床性洞察

第10章全球LAG-3标靶治疗的市场动态

第11章竞争情形

Table of Contents